Fludarabine
Questor share tips: Cancer specialist Antisoma remains a risky buy
...of GBP19.8m. The group is expecting a payment of GBP19.7m in the second half following the divestment of oral fludarabine, a treatment for chronic lymphatic leukaemia to Sanofi-Aventis.
Rituxan Approved for Chronic Lymphocytic Leukemia
...haven't responded to other anti-cancer drugs. It's administered with two other chemotherapy medications, fludarabine and cyclophosphamide. In a study of 817 people who hadn't been...
JavaScript and Flash are required to fully enjoy Evri
US FDA approves Rituxan/MabThera for the most common type of adult leukemia
...RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either...
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
...announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated...
Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
...are registered trademarks and Lumizyme™ is a trademark of Genzyme Corporation or its subsidiaries. Fludara® and Leukine® are registered trademarks licensed to Genzyme...
Biogen Idec Reports Full Year and Fourth Quarter 2009 Results
...and Biogen Idec announced that a three-year follow up of the pivotal Phase 3 CLL8 trial showed RITUXAN plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the...
Eventful Year Expected for Access Pharma
...Cancer (MASCC) on June 24-26 in Vancouver. Thiarabine is ACCP's next-generation nucleoside analogue (e.g. fludarabine, cladrabine) designed for the treatment of blood-based cancers such...
UPDATE 1-Glaxo, Genmab win EU backing for leukaemia drug
...lymphocytic leukaemia in patients who do not respond to Genzyme's <GENZ.O> Campath or the chemotherapy drug fludarabine. Recommendations for marketing approval by the agency's...
"Campath has proven to be a highly active single agent therapy across the spectrum of this disease, and Fludara is considered a backbone of CLL therapy. These trial results are anticipated to provide clinically meaningful data supporting Campath use in combination with Fludara in patients with relapsed or refractory CLL." "There is no cure for CLL, and it's important that we continue to develop new approaches to treat this significant unmet medical need," said Doug Burcz, Genzyme Vice President and General Manager, Campath, Fludara, Leukine. "Pending approval, the FluCAM dosing regimen used in the Phase 3 trial will extend the use of Campath by giving physicians an important alternative treatment regimen for their patients with progressive disease."
Genzyme's Campath Meets Primary Endpoint In Phase 3 Combination Therapy Trial For Chronic Lymphocytic Leukemia Medical News Today | 5 months ago
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
...European Union for the treatment of patients with CLL who are refractory to fludarabine and alemtuzumab. Fludarabine and alemtuzumab are standard therapies currently used to treat CLL...
Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations
...article is entitled "R-roscovitine (seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes...
BioVex Appoints Tim Hanke as VP Commercial Operations
...for the IL-2 franchise. He began his commercial career at Berlex Laboratories working on the launch of Fludara® for hematological malignancies. OncoVEX GM-CSF is a first in...
Genzyme Phase 3 Trial Of Campath/Fludara Combination Shows Potential Benefit In Second-Line CLL
...3 clinical trial comparing Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic...
